Assessing the risk of cytomegalovirus DNAaemia in allogeneic stem cell transplant recipients by monitoring oxidative-stress markers in plasma Free

Abstract

The level of antioxidants, such as thiol-containing tripeptide glutathione (GSH), in cytomegalovirus (CMV)-infected cells is notably increased. We previously showed that GSH levels in plasma, as measured by untargeted H nuclear magnetic resonance, are higher in allogeneic stem cell transplant (allo-SCT) recipients who subsequently develop CMV viraemia. We hypothesized that the net level of oxidative-stress markers present in plasma may be reduced in patients who develop CMV DNAaemia compared to those who do not. We serially monitored the levels of malondialdehyde (MDA) and carbonylated proteins (CPs) early after allo-SCT and assessed whether they could predict the occurrence of CMV DNAaemia. MDA levels were measured in 43 patients (28 had CMV DNAaemia) and CPs were quantified in 53 patients (38 patients developed CMV DNAaemia). The area under the curve (AUC) value for MDA, but not for CPs, was significantly lower in patients who subsequently developed CMV DNAaemia compared to those who remained DNAaemia-free (=0.043). A trend toward lower MDA AUC values was observed in episodes of CMV DNAaemia with faster CMV replicative kinetics and in those who reached higher peak CMV DNA levels. Moreover, receiver operating characteristic curve analyses indicated that the MDA biomarker had the predictive ability to discriminate between patients with or without subsequent CMV DNAaemia (AUC=0.69, 95 % confidence interval 0.51–0.85, =0.05). In summary, serial quantitation of MDA may be useful for individualizing antiviral prophylaxis therapies (targeted prophylaxis) in the upcoming era of new antiviral drugs with improved safety profiles.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000838
2017-07-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/7/1855.html?itemId=/content/journal/jgv/10.1099/jgv.0.000838&mimeType=html&fmt=ahah

References

  1. Görzer I, Guelly C, Trajanoski S, Puchhammer-Stöckl E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J Virol 2010; 84:7195–7203 [View Article][PubMed]
    [Google Scholar]
  2. Reddehase MJ, Balthesen M, Rapp M, Jonjić S, Pavić I et al. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 1994; 179:185–193 [View Article][PubMed]
    [Google Scholar]
  3. Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1β triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol 2006; 80:9151–9158 [View Article][PubMed]
    [Google Scholar]
  4. Prösch S, Wendt CE, Reinke P, Priemer C, Oppert M et al. A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology 2000; 272:357–365 [View Article][PubMed]
    [Google Scholar]
  5. Navarro D. Expanding role of cytomegalovirus as a human pathogen. J Med Virol 2016; 88:1103–1112 [View Article][PubMed]
    [Google Scholar]
  6. Boeckh M, Murphy WJ, Peggs KS. Reprint of: Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant 2015; 21:S19–S24 [View Article][PubMed]
    [Google Scholar]
  7. Romero PP, Blanco P, Giménez E, Solano C, Navarro D. An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. Future Virol 2015; 10:113–134 [View Article]
    [Google Scholar]
  8. Monleón D, Giménez E, Muñoz-Cobo B, Morales JM, Solano C et al. Plasma metabolomics profiling for the prediction of cytomegalovirus DNAemia and analysis of virus–host interaction in allogeneic stem cell transplant recipients. J Gen Virol 2015; 96:3373–3381 [View Article][PubMed]
    [Google Scholar]
  9. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013; 339:166–172 [View Article][PubMed]
    [Google Scholar]
  10. Frijhoff J, Winyard PG, Zarkovic N, Davies SS, Stocker R et al. Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal 2015; 23:1144–1170 [View Article][PubMed]
    [Google Scholar]
  11. Moore K, Roberts LJ. Measurement of lipid peroxidation. Free Radic Res 1998; 28:659–671 [View Article][PubMed]
    [Google Scholar]
  12. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R et al. Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med 2006; 10:389–406 [View Article][PubMed]
    [Google Scholar]
  13. Slade M, Goldsmith S, Romee R, Dipersio JF, Dubberke ER et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis 2017; 19:e12629 [View Article][PubMed]
    [Google Scholar]
  14. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: impact on human health. Pharmacogn Rev 2010; 4:118–126 [View Article][PubMed]
    [Google Scholar]
  15. Mikhed Y, Daiber A, Steven S. Mitochondrial oxidative stress, mitochondrial DNA damage and their role in age-related vascular dysfunction. Int J Mol Sci 2015; 16:15918–15953 [View Article][PubMed]
    [Google Scholar]
  16. Sari I, Cetin A, Kaynar L, Saraymen R, Hacioglu SK et al. Disturbance of pro-oxidative/antioxidative balance in allogeneic peripheral blood stem cell transplantation. Ann Clin Lab Sci 2008; 38:120–125[PubMed]
    [Google Scholar]
  17. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009; 48:143–157 [View Article][PubMed]
    [Google Scholar]
  18. Sabuncuoğlu S, Kuşkonmaz B, Uckun Çetinkaya D, Ozgüneş H. Evaluation of oxidative and antioxidative parameters in pediatric hematopoietic SCT patients. Bone Marrow Transplant 2012; 47:651–656 [View Article][PubMed]
    [Google Scholar]
  19. Biswas SK. Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox?. Oxid Med Cell Longev 2016; 2016:1–9 [View Article][PubMed]
    [Google Scholar]
  20. Reddehase MJ, Podlech J, Grzimek NK. Mouse models of cytomegalovirus latency: overview. J Clin Virol 2002; 25 Suppl 2:23–36 [View Article][PubMed]
    [Google Scholar]
  21. Chilet M, Aguilar G, Benet I, Belda J, Tormo N et al. Virological and immunological features of active cytomegalovirus infection in nonimmunosuppressed patients in a surgical and trauma intensive care unit. J Med Virol 2010; 82:1384–1391 [View Article][PubMed]
    [Google Scholar]
  22. Speir E, Shibutani T, Yu ZX, Ferrans V, Epstein SE. Role of reactive oxygen intermediates in cytomegalovirus gene expression and in the response of human smooth muscle cells to viral infection. Circ Res 1996; 79:1143–1152 [View Article][PubMed]
    [Google Scholar]
  23. Munger J, Bajad SU, Coller HA, Shenk T, Rabinowitz JD. Dynamics of the cellular metabolome during human cytomegalovirus infection. PLoS Pathog 2006; 2:e132-1175 [View Article][PubMed]
    [Google Scholar]
  24. Chambers JW, Maguire TG, Alwine JC. Glutamine metabolism is essential for human cytomegalovirus infection. J Virol 2010; 84:1867–1873 [View Article][PubMed]
    [Google Scholar]
  25. Tilton C, Clippinger AJ, Maguire T, Alwine JC. Human cytomegalovirus induces multiple means to combat reactive oxygen species. J Virol 2011; 85:12585–12593 [View Article][PubMed]
    [Google Scholar]
  26. Breusing N, Grune T, Andrisic L, Atalay M, Bartosz G et al. An inter-laboratory validation of methods of lipid peroxidation measurement in UVA-treated human plasma samples. Free Radic Res 2010; 44:1203–1215 [View Article][PubMed]
    [Google Scholar]
  27. Clari , Bravo D, Costa E, Muñoz-Cobo B, Solano C et al. Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia. Diagn Microbiol Infect Dis 2013; 75:207–209 [View Article][PubMed]
    [Google Scholar]
  28. Solano C, Giménez E, Piñana JL, Vinuesa V, Poujois S et al. Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood. Bone Marrow Transplant 2016; 51:718–721 [View Article][PubMed]
    [Google Scholar]
  29. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999; 190:177–182 [View Article][PubMed]
    [Google Scholar]
  30. Muñoz-Cobo B, Solano C, Costa E, Bravo D, Clari et al. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies. Biol Blood Marrow Transplant 2011; 17:1602–1611 [View Article][PubMed]
    [Google Scholar]
  31. Shacter E, Williams JA, Lim M, Levine RL. Differential susceptibility of plasma proteins to oxidative modification: examination by Western blot immunoassay. Free Radic Biol Med 1994; 17:429–437 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000838
Loading
/content/journal/jgv/10.1099/jgv.0.000838
Loading

Data & Media loading...

Most cited Most Cited RSS feed